Interestingly, we observed that a significant number of patients with low-risk prostate cancer were being staged with CT scans (24.5% of the cohort), bone scans (18.0% of cohort), and, in rare cases, PSMA PET scans (0.5% of the cohort). The gene discussed is FOLH1; the disease is prostate carcinoma.